Introduction
Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in the Western world and is estimated to be present in one-third of the US population [1, 2] . A certain subset (up to 15%) of NAFLD patients has nonalcoholic steatohepatitis (NASH) that is characterized by progressive inflammation and hepatic fibrosis leading to cirrhosis, hepatocellular cancer, liver failure, and premature mortality [3] . Due to lack of a reliable noninvasive test, NASH remains a histological diagnosis requiring liver biopsy [4] . Efforts to identify the small subset of patients with NASH from the larger NAFLD patient population in order to avoid unnecessary liver biopsy have led to the identification of various clinical and biochemical variables predictive of advanced fibrosis associated with NASH [4] [5] [6] [7] [8] . Few investigators have also proposed complex scores based on a combination of these variables [7, 9, 10] . The presence of serum autoantibodies, such as antinuclear antibody (ANA) and smooth muscle antibody (SMA), has been reported to be associated with a higher inflammatory grade and advanced fibrosis, prompting some experts to recommend liver biopsy in NAFLD patients with positive autoantibodies [11] [12] [13] .
Previous studies examining the prevalence of serum autoantibodies (ANA and SMA) in patients with NAFLD reported a wide range of prevalence rates depending on the threshold values used for an abnormal titer [11, 12, [14] [15] [16] [17] . However, these studies have been limited by heterogeneity with regard to study design, sample size, and referral bias. Adams et al. [11] reported an association between the presence of autoantibodies (ANA [ 1:40) with significantly higher fibrosis stage and inflammatory grade in 225 patients with liver biopsy proven NAFLD. Niwa et al. [13] reported a significantly greater degree of portal inflammation, hepatocellular ballooning, and advanced histological features of NASH in 35 ANA-positive NASH patients compared to 36 ANA-negative NASH patients in a casecontrol study. Interestingly, the degree of steatosis was lower in the high-titer (C1:320) ANA group (P = 0.01). Loria et al. [18] also showed that the autoantibody positive subjects exhibited severe steatosis less frequently (1 of 7) than the autoantibody-negative (50%) group. An association between patients with high titer autoantibodies and insulin resistance in this cohort led the investigators to hypothesize that autoantibodies may represent an epiphenomenon of insulin resistance leading to the progression of NAFLD [19] . However, this finding was not confirmed by Adams et al. in their cohort [11, 20] . Thus, the studies examining the relationship between disease severity and the presence of autoantibodies have reported conflicting results. The goal of the current study was to determine the prevalence of significant autoantibodies (defined as ANA [ 1:160 or SMA [ 1:40 or both) in a large cohort of well-characterized NAFLD patients. A second aim of the study was to systematically evaluate the relationship between the presence of these autoantibodies, presence of diabetes/insulin resistance, and the histologic severity of NAFLD.
Methods
The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) has successfully conducted two prospective clinical trials in adult patients with NAFLD and NASH [21, 22] . The baseline demographic, laboratory, and histological data from all adult patients from two prospective studies (NAFLD Database study and the PIVENS Trial, Clinical Trial No. NCT00063622) were considered for this study. The NAFLD Database Study is an observational study of patients with definite NAFLD, suspected NAFLD, and cryptogenic cirrhosis [21] . The PIVENS trial is a randomized, multicentre, double masked, placebo controlled trial that evaluated pioglitazone or vitamin E in the treatment of biopsy-proven NASH [22] . These studies were conducted across eight clinical centres with a central Data Coordinating Centre (see Appendix for roster). Study protocols were approved by all participating centre institutional review boards. Inclusion criteria for this study were patients in whom autoantibodies were detected within 2 years of their liver biopsy. The titers of autoantibodies were considered significant if ANA C 1:160 or SMA C 1:40 or both. Among patients who had antibodies detected by an indirect immunofluorescence method, ANA C3 U and SMA C30 U were considered clinically significant. These ''cut-off values'' for autoantibody titers were chosen a priori to increase the specificity and to improve the distinction between clinically significant and positive ANA and SMA titers that can occur in normal individuals [23] . Liver biopsies were reviewed centrally in a systematic blinded fashion by the Pathology subcommittee and scored for various histologic features, including steatosis, lobular inflammation, hepatocellular injury (ballooning), fibrosis, NAFLD activity score (NAS) and steatohepatitis diagnosis (i.e., ''not steatohepatitis'', ''borderline'', ''definite steatohepatitis'') [24] . NAS is a composite score taking into consideration the degree of steatosis, inflammation, and hepatocyte ballooning [24] .
Statistical analysis
Histological features were compared between those with and without significant titers of autoantibodies. Sample size calculation for this study was based on fibrosis ranging from 0 to 6 (continuous response variable) as per the standard protocol used by the NASH CRN Pathology subcommittee [24] with 1:1 ratio between NAFLD patients with and without autoimmune antibodies. We assumed that the fibrosis within each subject group was normally distributed with standard deviation 1. To detect a difference of at least 2 points (33%) in fibrosis score, we would need to study 145 subjects with autoantibodies and 145 control subjects to be able to reject the null hypothesis that the population means of the autoantibody positive and control groups are equal with probability (power) 0.8. The type 1 error probability associated with this test of this null hypothesis is 0.05. P values were determined by a Chisquare test for categorical variables and by the Wilcoxon rank-sum test for continuous variables. Nominal, two-sided P values were used and considered statistically significant if P \ 0.05. Multiple logistic regression analyses were performed to examine the relationship between the presence of significant ANA/ASMA and histological variables. Separate models were fit for each histologic variable as the outcome and all models were adjusted for age, gender, race, body mass index (BMI), and diabetes. Analyses were performed using SAS statistical software (version 9; SAS Institute Inc., Carey, NC, USA).
Results
A total of 864 patients who participated in the two NASH CRN studies were included in this study. The mean age at enrollment for these studies was 49 ± 12 years and the mean BMI was 34 ± 6 kg/m 2 in the entire cohort. 64% were females and 84% of the cohort were Caucasian. Diabetes (type 1 or 2) was present in 25.8% and in those who did not have a diagnosis of diabetes, the median HOMA-IR score of 3.8 (inter-quartile range: 2.4-6.8) was indicative of their underlying insulin resistance. A number of 182 patients (21%) had significant titers of autoantibodies. There were no statistically significant differences between the two groups with regard to gender, BMI, race, presence of diabetes, or HOMA-IR score ( Table 1) .
Analysis of histological features showed that patients with positive autoantibodies were less likely to have moderate-to-severe steatosis (C33%) compared to those who did not have autoantibodies (57.1 vs. 42.9%, P = 0.0006). The mean NAS was also lower in patients with significant autoantibodies compared to those without (Table 2 ). Chronic portal inflammation (more than mild) was significantly higher (31.6 vs. 22.0%, P = 0.03) compared to patients without autoantibodies. Subgroup analysis of histological features in patients with either ANA or SMA titer C1:640 positivity showed similar demographic and histological features compared to patients without autoantibodies (Supplementary Table 1 ). Multiple regression analysis after adjusting for age, gender, BMI, race, and diabetes, the presence of autoantibodies in significant titer was independently associated with lower prevalence of moderate-to-severe steatosis [odds ratio (OR), 0.58; 95% confidence interval (CI), 0.41-0.82; P = 0.01] on liver histology (Table 3) .
Discussion
Autoantibodies, such as ANA and ASMA, are often discovered during the routine evaluation of patients with suspected NAFLD and their presence leads to concerns about autoimmune hepatitis; the standard treatment for autoimmune hepatitis includes corticosteroids which may lead to unnecessary complications in patients with NA-FLD. In the current multicentre study from across eight centres in the US, we observed that significant titers of autoantibodies were detectable in 21% of the study cohort, demonstrating that presence of autoantibodies is common 
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Hepatol Int (2012) 6:379-385 381 in this population. This prevalence rate is similar to the two previous studies with much smaller cohorts of liver biopsyproven NAFLD patients [11, 18] . Previous studies evaluating the relationship between the presence of these antibodies with insulin resistance, severity of liver histology, and diagnosis of NASH have yielded conflicting results [11, 12, 18] . We observed that the prevalence of diabetes (type 1 and 2) and the median HOMA-IR score were not significantly different between NAFLD patients with and without significant autoantibodies. Our results indicate that the presence of autoantibodies may be an epiphenomenon and may not indicate underlying insulin resistance. This is consistent with the earlier findings by Adams et al. in a smaller cohort of patients [20] . Our study does not confirm the previously reported observation that the presence of autoantibodies in significant titer is associated with advanced fibrosis as systematic evaluation of various histological features, such as hepatocyte ballooning, lobular inflammation, and advanced fibrosis did not reveal any statistically significant differences between the two groups. Similarly, histologic evidence of ''definite'' NASH did not differ significantly between the two groups. NAS was lower in those with significant autoantibodies compared to those without, likely due to the lesser degree of hepatic steatosis in this group. Overall, systematic comparison of various histological features did not reveal any significant difference between NAFLD patients with and without significant autoantibodies with the exception of the amount of steatosis. The finding of a significantly lower grade of steatosis in patients with significant autoantibodies is intriguing and is consistent with the two previous studies [13, 18] . Previous reports describing the presence of autoantibodies in patients with NAFLD and NASH have not yielded insights into the possible mechanisms for this phenomenon. Recently, Syn et al. [25] reported that hepatic natural killer T (NKT) cell accumulation was associated with more advanced NAFLD. Concomitant activation of autoantibody production with activation of NKT cells has been previously reported [26, 27] . We speculate that autoantibody production in NAFLD subjects may be a consequence of hepatic NKT cell accumulation. In support of this hypothesis, a significant increase (31.6 vs. 22.0%) in chronic portal inflammation (more than mild) was present in patients with autoantibodies compared to patients without autoantibodies ( Table 2) . Loria et al. previously proposed the existence of an ''autoimmune hepatitis-NAFLD'' overlap syndrome [18] . However, treatment with corticosteroids in this subgroup of patients was not associated with biochemical or histological improvement.
Certain aspects of our study deserve further discussion. Since there are multiple causes for ANA positivity (medications, chronic liver disease, seropositive arthritis, and advanced age) [23, 28] , a concomitant evaluation of ANA positivity with hyperglobulinemia could potentially indicate a phenotype or a co-existing autoimmune hepatitis or more advanced disease than an isolated ANA. However, we raised the negative cut-off titer from 1:40 to 1:160 in order to improve the distinction between clinically significant ANA and ANA occurring in normal individuals from other causes. In addition, our study cohort consisted of adult NAFLD patients (with or without significant autoantibodies) who were selected for inclusion in the study based on the absence of another concomitant liver disease. Therefore, patients with clinical evidence of autoimmune hepatitis were excluded. In contrast to the present study, a previous study from NASH CRN evaluating the significance of autoimmune serology in pediatric NAFLD reported a statistically significant increased prevalence of SMA positivity with increasing NAS [29] . Therefore, our findings may not be applicable to the pediatric NASH/ NAFLD population. We also analyzed the study cohort after categorization into three study groups: no antibody detected (ANA \ 1:40) versus nonsignificant titer antibody (ANA 1:40-1:80) and significant titer antibody (ANA [ 1:160) in order to examine any gradient of features that were important and could lead to a more criteria-based definition. This analysis yielded similar conclusions (data not shown). Additional analysis included limiting the study cohort to those who had histology and labs within 6 months yielded a sample size of 678 (antibody positive: 148, antibody negative: 530). This ratio is very similar to the cohort reported in this study (antibody positive: 182, antibody negative: 682). Since the ratio is very similar (0.26), we do not anticipate a different conclusion either with 6 months or 2 years cut off for study entry criteria. Alternative inclusion criteria with limitation of the time interval between liver biopsy and autoantibody to 3 months along with the presence of ANA titer C 1:40 or ASMA titer C 1:40 or both, yielded a prevalence of 12.6%. Analysis of this cohort yielded similar conclusion with autoantibody positive group having a lower prevalence of severe steatosis ([33%) (44.9 vs. 58.7%, P = 0.004).
In summary, the current study found that the presence of a positive ANA or SMA was not associated with advanced histological features and presence of ''definite NASH'' among patients with NAFLD. However, we did identify an association between a lower grade of steatosis and possible increased portal inflammation in NAFLD patients with significant titers of autoantibodies.
